FindTrial
Sign In

Biopsy Specimen

PROCEDURE2 trials

Sponsors

National Cancer Institute (NCI), Mayo Clinic

Conditions

Hematopoietic and Lymphoid System NeoplasmMetastatic Colorectal CarcinomaMetastatic Lung Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Pancreatic CarcinomaRefractory Colorectal CarcinomaRefractory Lung Small Cell CarcinomaRefractory Malignant Solid Neoplasm

Phase 1

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Active, not recruitingNCT02595931
National Cancer Institute (NCI)Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm +15
Start: 2016-07-22End: 2027-03-06Updated: 2026-04-03

Unknown Phase

Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal
RecruitingNCT05530759
Mayo ClinicHematopoietic and Lymphoid System Neoplasm, Metastatic Malignant Solid Neoplasm
Start: 2022-06-29End: 2028-04-07Target: 50Updated: 2025-04-02

Related Papers

Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).
2025-11-01
NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors.
Journal of Clinical Oncology2022-06-0112 citations